Traditional Chinese Medicine in Patients With Primary Sjogren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- PMID: 34651000
- PMCID: PMC8505713
- DOI: 10.3389/fmed.2021.744194
Traditional Chinese Medicine in Patients With Primary Sjogren's Syndrome: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Abstract
Background: Sjogren's syndrome (SS) is a chronic inflammatory autoimmune disease mainly characterized by dryness, fatigue, and pain. Current therapies for SS in Western medicine are limited. The purpose of this clinical study was to explore the efficacy and safety of using a traditional Chinese medicine (TCM) formula on patients with primary SS. Methods: We performed a 12-week, randomized, double-blinded, placebo-controlled clinical trial at Chung Shan Medical University Hospital. We included 42 patients with SS between the ages of 20 and 80 years who met the classification criteria of the American and European Consensus Group (AECG). Patients who had other severe systemic manifestations or diseases were excluded from this trial. After screening, patients were randomly assigned to the TCM treatment group or placebo group (ratio of 2:1). We treated the TCM group with 6 g of Gan-Lu-Yin granules after breakfast and 6 g of Jia-Wei-Xiao-Yao-San combined with 1 g of Suan-Zao-Ren-Tang and 1 g of Ye-Jiao-Teng every night after dinner. Patients in the control group were treated with a placebo with the same appearance and flavor but only one-tenth the dosage of that received by the treatment group. The European League Against Rheumatism Sjogren's Syndrome Patient-Reported Index (ESSPRI) was used as the primary endpoint at week 12. Secondary endpoints were the Sjogren's Syndrome Disease Activity Index (SSDAI), physician global assessment (PGA), visual analogue scale (VAS), Multidimensional Fatigue Inventory, Medical Outcomes Survey Short Form-36, and the Pittsburgh Sleep Quality Score (PSQI). Adverse events were also recorded. Results: Of the 42 randomized patients, 28 patients were assigned to the TCM treatment group and 14 patients were assigned to the controlled group. During the study period, 5 patients withdrew from the TCM group and 7 withdrew from the control group. At week 12, the ESSPRI scores of both groups had improved. The ESSPRI score of the treatment group decreased by 0.62 (95% CI P = 0.557) and that of the placebo group decreased by 0.91 (P = 0.557). However, no significant difference was observed between the two groups. Sleep duration in the PSQI was -0.61, which exhibited an improvement of more than the -0.21 compared with the placebo group (P = 0.914). Conclusion: At week 12, the ESSPRI scores did not reveal that the use of the TCM formula was efficacious for treating patients with Sjogren's syndrome. However, the PSQI scores indicated that this formula could prolong patient sleep duration. We also found that this formula could decrease the blood pressure of patients.
Keywords: Gan-Lu-Yin; Jia-Wei-Xiao-Yao-San; Sjogren's syndrome; efficacy; randomized clinical trial; safety.
Copyright © 2021 Chen, Lai, Yu, Chen, Hsieh, Hsu and Wei.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8505713/bin/fmed-08-744194-g0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8505713/bin/fmed-08-744194-g0002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/8505713/bin/fmed-08-744194-g0003.gif)
Similar articles
-
The efficacy and safety of total glucosides of peony in the treatment of primary Sjögren's syndrome: a multi-center, randomized, double-blinded, placebo-controlled clinical trial.Clin Rheumatol. 2019 Mar;38(3):657-664. doi: 10.1007/s10067-018-4315-8. Epub 2018 Oct 2. Clin Rheumatol. 2019. PMID: 30280368 Clinical Trial.
-
Traditional Chinese medicine compound ShengJinRunZaoYangXue granules for treatment of primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled clinical trial.Chin Med J (Engl). 2014;127(15):2721-6. Chin Med J (Engl). 2014. PMID: 25146603 Clinical Trial.
-
Outcome measures for primary Sjögren's syndrome: a comprehensive review.J Autoimmun. 2014 Jun;51:51-6. doi: 10.1016/j.jaut.2013.12.010. Epub 2014 Jan 8. J Autoimmun. 2014. PMID: 24411404 Review.
-
European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.Arthritis Care Res (Hoboken). 2013 Aug;65(8):1358-64. doi: 10.1002/acr.21991. Arthritis Care Res (Hoboken). 2013. PMID: 23436737
-
EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome.Ann Rheum Dis. 2011 Jun;70(6):968-72. doi: 10.1136/ard.2010.143743. Epub 2011 Feb 22. Ann Rheum Dis. 2011. PMID: 21345815
Cited by
-
Exploring the Psychiatric Manifestations of Primary Sjögren's Syndrome: A Narrative Review.Int J Rheumatol. 2024 May 14;2024:5520927. doi: 10.1155/2024/5520927. eCollection 2024. Int J Rheumatol. 2024. PMID: 38774059 Free PMC article. Review.
-
Efficacy of non-pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases.RMD Open. 2023 Aug;9(3):e003350. doi: 10.1136/rmdopen-2023-003350. RMD Open. 2023. PMID: 37604639 Free PMC article.
-
Effect of adipose tissue-derived stem cells therapy on clinical response in patients with primary Sjogren's syndrome.Sci Rep. 2023 Aug 19;13(1):13521. doi: 10.1038/s41598-023-40802-5. Sci Rep. 2023. PMID: 37598237 Free PMC article. Clinical Trial.
-
Relationship between Chinese Herbal Medicine Use and Risk of Sjögren's Syndrome in Patients with Rheumatoid Arthritis: A Retrospective, Population-Based, Nested Case-Control Study.Medicina (Kaunas). 2023 Mar 30;59(4):683. doi: 10.3390/medicina59040683. Medicina (Kaunas). 2023. PMID: 37109641 Free PMC article.
-
Commentary: Efficacy and safety of acupuncture on symptomatic improvement in primary Sjögren's syndrome: A randomized controlled trial.Front Med (Lausanne). 2023 Jan 4;9:1098862. doi: 10.3389/fmed.2022.1098862. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36687408 Free PMC article. No abstract available.
References
LinkOut - more resources
Full Text Sources
Miscellaneous